Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

As the COVID-19 pandemic ravaged the country last year, the US worked with pharmaceutical giants to quickly make and produce vaccines. Now that vaccine shots are getting into more arms, Johnson & Johnson's CEO Alex Gorsky hopes the US continues to partner with drugmakers after the pandemic ends.

Johnson & Johnson's CEO doesn't want to go back to 'business as usual' after the pandemic and hopes public-private partnerships among pharmaceutical firms continue (JNJ)

Global X Robotics & Artificial Intelligence ETF

ProShares Long Online/Short Stores ETF

Global X Cloud Computing ETF

Fidelity MSCI Materials Index ETF

iShares Nasdaq Biotechnology ETF

Amplify Online Retail ETF

First Trust Nasdaq Artificial Intelligence & Robotics ETF

First Trust Cloud Computing ETF

SPDR S&P Biotech ETF

Energy Select Sector SPDR Fund

Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.

5 ETF Investing Areas for March to Boost Returns

Johnson & Johnson (JNJ) Presents at Cowen 41st Annual Health Care Conference (Transcript)

AstraZeneca

Costco

Lockheed Martin

PepsiCo

Procter & Gamble

Walmart

Stocks that are worth considering for retirement investors. Low beta stocks with strong fundamentals and a healthy dividend yield.

7 Stocks for Any Retiree to Consider

Johnson & Johnson's single-dose Covid-19 vaccine received emergency use approval from the U.S. FDA late last week, with a rollout expected to begin shortly. So what does this mean for J&J's stock?

Can Johnson & Johnson's Stock Benefit From Its Covid-19 Vaccine?

Merck

Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.

Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply

Here's What the FDA Liked About Johnson & Johnson's COVID Vaccine

Johnson & Johnson (JNJ) Presents at Raymond James 42nd Annual Institutional Investors Conference Call Transcript

Johnson & Johnson CEO Alex Gorsky discussed on Tuesday the company's unprecedented partnership with rival Merck to boost production of its Covid-19 vaccine.

Johnson & Johnson CEO on Merck vaccine partnership: 'Extraordinary times take extraordinary efforts'

In the latest trading session, Johnson & Johnson (JNJ) closed at $159.02, marking a -0.19% move from the previous day.

Johnson & Johnson (JNJ) Stock Moves -0.19%: What You Should Know

Merck will help rival drugmaker Johnson & Johnson produce its single-dose coronavirus vaccine, the White House said Tuesday. The two pharmaceutical giants have reached a “historic manufacturing partnership” to ramp up J&J's supply of its COVID-19 shot, which the feds cleared for emergency use on Saturday, White House Press Secretary Jen Psaki said.

Merck to help Johnson & Johnson produce COVID vaccine

Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.

J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine

Merck will reportedly step in to help Johnson & Johnson manufacture its coronavirus vaccine in a deal that binds two rival vaccine stocks. J&J is reportedly behind in production.

Merck, J&J Reportedly Forge Covid Vaccine Alliance — Here's What You Need To Know

The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki said on Tuesday.

White House using Defense Production Act to equip Merck plants for Johnson & Johnson vaccine

ARK Innovation ETF

iShares Core S&P 500 ETF

SPDR S&P 500 ETF Trust

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Financial Select Sector SPDR Fund

We have highlighted some equity ETFs that gained immense popularity last month and will likely to do so, given the encouraging development in vaccines from likes of Johnson & Johnson (JNJ) as well as upbeat manufacturing and consumer spending data.

6 Red-Hot ETFs of February

Two of the country's largest pharma companies will partner to speed up COVID-19 vaccine production. President Joe Biden will announce a partnership between Merck and Johnson & Johnson, senior administration officials told The Washington Post.

Merck will reportedly help produce Johnson & Johnson COVID-19 vaccine shots after failing to make its own (MRK, JNJ)

The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.

Coronavirus Update: U.S. COVID vaccine supply to be boosted by Merck helping make J&J vaccine

Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, a White House official said.

Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official

U.S. President Joe Biden will announce that Merck & Co (NYSE: MRK) will help manufacture its rival Johnson & Johnson's (NYSE: JNJ) newly authorized coronavirus vaccine to boost the supply, Washington Post reports. The officials started looking for additional manufacturing capacity amid concerns about Johnson & Johnson's production delays.

Merck To Offer Hand With JNJ COVID-19 Vaccine Production, Biden Administration Says: Report

President Joe Biden announced Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine.

Biden to announce Merck will help make Johnson & Johnson's Covid vaccine

Johnson & Johnson (NYSE: JNJ) is waiting on regulatory approval of a new, larger plant operated by Catalent Inc (NYSE: CTLT) to start large-scale U.S. deliveries of its recently approved single-dose COVID-19 vaccine, Reuters reports. J&J Chief Scientific Officer Paul Stoffels said that the company would ship around 4 million doses from a smaller plant already up and running in the U.S. this week.

JNJ Accelerated COVID-19 Vaccine Shipment Dependent On New Plant Approval

Biden reportedly set to announce Merck assistance in J&J vaccine manufacturing

ACM Research

Crown Hlds

Deere & Company

iRobot

EnPro Industries

The U.S. manufacturing sector continues to expand after the COVID-induced slump early last year, making it wise to look at names like ACM Research (ACMR), EnPro Industries (NPO) and iRobot (IRBT).

5 Stocks to Buy Amid Continued Expansion in Manufacturing

There were 47 reports of severe allergic reactions in those who received Pfizer's vaccine and 19 cases in those who received Moderna's as of Jan. 18, CDC said.

CDC says J&J Covid vaccine is OK for people who have allergic reaction to Pfizer or Moderna's

Biotech ETFs are climbing again on Monday, as the the CDC approved Johnson & Johnson's coronavirus vaccine for emergency use this past weekend. The Centers for Disease Control and Prevention advisory panel voted unanimously Sunday to recommend the use of Johnson & Johnson's one-shot coronavirus vaccine for people aged 18 years and older.

News for Johnson & Johnson Stock (JNJ)